ABUS

Arbutus BiopharmaB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

25%

Probability

Target price

$7.35

+72.5% vs current

Most likely

Base case

50%

Probability

Target price

$5.68

+33.3% vs current

B-

Bear case

25%

Probability

Target price

$3.00

-29.6% vs current

AI sentiment snapshot

Latest data as of 2026-03-26

AI commentary

Recent corporate update and Q4/2025 results refreshed focus on cash runway and corporate strategy; coverage tone is cautiously constructive given limited near-term program catalysts and a modest analyst target range [#8-K-2026-03-23] [#PR-undated]. Market commentary emphasizes financing/partnering as the pivotal near-term call [#SERP-3].

RankAlpha Sentiment AI - 2026-03-26

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-24catalystNext quarterly results / corporate update (Q1 2026)High impact

Market will re-price on Q1 2026 operational/financial detail and management commentary following the Q4/2025 release; investors should watch cash/runway commentary and program updates referenced in the March 23, 2026 corporate update [#8-K-2026-03-23].

2027-03-26catalystBalance-sheet-driven financing or partnering decision within 12 monthsHigh impact

Arbutus reported cash, cash equivalents and marketable securities of ~$91.5M at year-end 2025 per the March 23, 2026 release; that runway math makes a financing, partnership, or explicit runway-extension plan the likely company action within the next year, which would materially affect valuation [#8-K-2026-03-23] [#PR-undated].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-03-26 • Updated nightlySource: Internal modelMethodology